BacMam Virus Transduced Cardiomyoblasts Can Be Used for Myocardial Transplantation Using AP-PEG-A Microcapsules: Molecular Cloning, Preparation, and In Vitro Analysis

Abstract EN

The potential of genetically modified cardiomyoblasts in treating damaged myocardium is well known.

However, efficient delivery of these cells is of major concern during treatment.

The limiting factors are the massive cell death that occurs soon after their intramyocardial transplantation into the beating heart.

To address these problems, we generated recombinant baculoviruses (BacMam viruses) which efficiently transduced cardiomyoblast cells under optimized conditions.

These genetically modified cells were then protected in a new polymeric microcapsule using poly-ethylene-glycol (PEG), alginate, and poly-L-lysine (PLL) polymers for efficient delivery.

Results showed that microcapsules maintain cell viability and support cell proliferation for at least 30 days.

The capsules exhibit strong immunoprotective potential and have high mechanical and osmotic stability with more than 70% intact capsules.

The encased transduced cells showed a rapid transgene expression inside the capsule for at least 15 days.

However, preclinical studies are needed to further explore its long-term functional benefits.